RenovoRx Inc. (RNXT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, RNXT scores 31 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 3 of 20, with ROIC of -35% and an FCF yield of -16.32%, indicating the business is consuming rather than generating cash relative to its capital base. The Whale 13F Flow pillar scores 11 of 20, reflecting institutional accumulation and options positioning, which is the strongest pillar and represents the main upside-driver narrative in the data. The Insider Conviction pillar scores 3 of 20, based on SEC Form 4 and Congressional PTR cluster flow, signaling weak insider-side conviction. The Macro Regime Fit pillar scores 6 of 20, with a beta of 1.0 and sector sensitivity noted. The Forensic Balance Sheet pillar scores 8 of 20, anchored by an Altman Z of 0.4 (a distress-range reading), a Piotroski F of 4/9, and a Debt/Equity of 0.5. For a prospective investor, the practical implication is that the score is driven by persistent losses and cash burn rather than any single weak metric; the institutional-flow pillar is the only meaningful counterweight. Any valuation case would depend on the company's ability to reach cash generation, which the source data does not show occurring within the reported periods.

Per the profile, RenovoRx Inc. (RNXT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, the company is associated with a cancer drug-delivery device, with physicians' expanding use of that device referenced as a discussion topic. Revenue per the SEC financials was $1.1M in FY 2025 and $0.0M in FY 2024 and FY 2023. Source data does not provide a complete description of customers or the detailed revenue model.

Per the market data, gross margin is 70.9%, while operating and net margins are each -60%, and ROIC is -35%. Per the RQD pillars, the Altman Z-Score is 0.4 and the Piotroski F-Score is 4/9, with Debt/Equity at 0.5. Reported cash declined from $7.2M in FY 2024 to $7.0M in FY 2025 while free cash flow remained negative in each reported year. Source data does not provide a debt figure for any period.

Per the recent news wire, five items reference RNXT, all flagged YELLOW with "MARKET WIRE" impact labels. Headlines reference a cash-burn discussion (Simply Wall St), an SEC filing dated October 16, 2026 (Stock Titan), a Q3'26 earnings revenue estimate of 1.06M USD (TradingView), a mention among health care movers in an after-market session (Benzinga), and an upcoming discussion on physicians' expanded use of the device (Stock Titan). Risk watch items include the cash-burn focus and the upcoming Q3'26 earnings. Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links or proprietary signals recorded.

• What is the company's debt position in each reported period, given that debt is recorded as N/A throughout the financials?
• What are the trailing and forward earnings and valuation multiples, which are not provided in the source data?
• What is the underlying holder composition behind the Whale 13F Flow pillar score?
• What commercial milestones or revenue drivers support the Q3'26 revenue estimate referenced in the news wire?
• What is the company's cash runway at the current burn rate, relative to the reported $7.0M cash position?